The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Novel anticancer therapeutics targeting telomerase
Open accessAbstract
Telomeres are protective caps at the ends of human chromosomes. Telomeres shorten with each successive cell division in normal human cells whereas, in tumors, they are continuously elongated by human telomerase reverse transcriptase (hTERT). Telomerase is overexpressed in 80-95% of cancers and is present in very low levels or is almost undetectable in normal cells. Because telomerase plays a pivotal role in cancer cell growth it may serve as an ideal target for anticancer therapeutics. Inhibition of telomerase may lead to a decrease of telomere length resulting in cell senescence and apoptosis in telomerase positive tumors. Several strategies of telomerase inhibition are reviewed, including small molecule inhibitors, antisense oligonucleotides, immunotherapies and gene therapies, targeting the hTERT or the ribonucleoprotein subunit hTER. G-quadruplex stabilizers, tankyrase and HSP90 inhibitors targeting telomere and telomerase assembly, and T-oligo approach are also covered. Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001). Most of these agents have entered phase I and II clinical trials in patients with various tumors, and have shown good response rates as evidenced by a reduction in tumor cell growth, increased overall disease survival, disease stabilization in advanced staged tumors and complete/partial responses. Most therapeutics have shown to be more effective when used in combination with standard therapies, resulting in concomitant telomere shortening and tumor mass shrinkage, as well as preventing tumor relapse and resistance to single agent therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TRF2 Protects Human Telomeres from End-to-End Fusions
van Steensel, B., Smogorzewska, A., & de Lange, T. (1998) · Cell · doi:10.1016/s0092-8674(00)80932-0 · Cited by 1,709
Telomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · cited 5×
“Another strategy is targeting the telomera se subunit indirectly with G-quadru plex stabilizers, Tankyrase or HSP90 inhibitors, thus blocking telomerase access to telomere s or inhibiting binding of telomerase-ass ociated proteins leading to telomere uncapping and cell apoptosis.(3,11) One of the most recent approach…”
BackgroundMethodInfluentialSu, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect
Salvati, E., Leonetti, C., Rizzo, A., Scarsella, M., Mottolese, M., Galati, R., Sperduti, I., Stevens, M. F. G., D’Incalci, M., Blasco, M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32461 · Cited by 266
Telomerase-Specific Replication-Selective Virotherapy for Human Cancer
Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1075-3 · Cited by 262
Targeting telomerase for cancer therapeutics
Shay, J. W., & Keith, W. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604209 · Cited by 171
Djojosubroto, M. W., Chin, A. C., Go, N., Schaetzlein, S., Manns, M. P., Gryaznov, S., Harley, C. B., & Rudolph, L. K. (2005) · Hepatology · doi:10.1002/hep.20822 · Cited by 151 · cited 1×
“Hepatoma (liver cancer) Dose-dependent inhibition of TA and tumor cell growth in vitro and in vivo ; reduction of cell proliferation and tumor growth; increased apoptosis and sensitivity due to doxorubicin treatment.(124)”
BackgroundHochreiter, A. E., Xiao, H., Goldblatt, E. M., Gryaznov, S. M., Miller, K. D., Badve, S., Sledge, G. W., & Herbert, B.-S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2760 · Cited by 146
Antiadhesive Effects of GRN163L—An Oligonucleotide N3′→P5′ Thio-Phosphoramidate Targeting Telomerase
Jackson, S. R., Zhu, C.-H., Paulson, V., Watkins, L., Dikmen, Z. G., Gryaznov, S. M., Wright, W. E., & Shay, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2306 · Cited by 72
Cited by
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
Telomeres: history, health, and hallmarks of aging
Chakravarti, D., LaBella, K. A., & DePinho, R. A. (2021) · Cell · doi:10.1016/j.cell.2020.12.028 · Cited by 637
Thakur, A., Singla, R., & Jaitak, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.010 · Cited by 489
Metadata
- Authors
- Ruden, M., & Puri, N.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 39
- Issue
- 5
- Pages
- 444-456
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2100215079
- Cited by
- 310
- References
- 11
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
